JP2006506350A5 - - Google Patents

Download PDF

Info

Publication number
JP2006506350A5
JP2006506350A5 JP2004536018A JP2004536018A JP2006506350A5 JP 2006506350 A5 JP2006506350 A5 JP 2006506350A5 JP 2004536018 A JP2004536018 A JP 2004536018A JP 2004536018 A JP2004536018 A JP 2004536018A JP 2006506350 A5 JP2006506350 A5 JP 2006506350A5
Authority
JP
Japan
Prior art keywords
alkyl
substituted
ring
diethyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2004536018A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006506350A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/024805 external-priority patent/WO2004024719A1/en
Publication of JP2006506350A publication Critical patent/JP2006506350A/ja
Publication of JP2006506350A5 publication Critical patent/JP2006506350A5/ja
Abandoned legal-status Critical Current

Links

JP2004536018A 2002-09-12 2003-08-27 置換1,4−ピラジン誘導体 Abandoned JP2006506350A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41026102P 2002-09-12 2002-09-12
PCT/US2003/024805 WO2004024719A1 (en) 2002-09-12 2003-08-27 Substituted 1,4-pyrazine derivatives

Publications (2)

Publication Number Publication Date
JP2006506350A JP2006506350A (ja) 2006-02-23
JP2006506350A5 true JP2006506350A5 (cg-RX-API-DMAC10.html) 2006-09-21

Family

ID=31994096

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004536018A Abandoned JP2006506350A (ja) 2002-09-12 2003-08-27 置換1,4−ピラジン誘導体

Country Status (10)

Country Link
US (1) US20040116444A1 (cg-RX-API-DMAC10.html)
EP (1) EP1539736A1 (cg-RX-API-DMAC10.html)
JP (1) JP2006506350A (cg-RX-API-DMAC10.html)
AR (1) AR041125A1 (cg-RX-API-DMAC10.html)
AU (1) AU2003269949A1 (cg-RX-API-DMAC10.html)
BR (1) BR0314139A (cg-RX-API-DMAC10.html)
CA (1) CA2494975A1 (cg-RX-API-DMAC10.html)
MX (1) MXPA05002418A (cg-RX-API-DMAC10.html)
TW (1) TW200503717A (cg-RX-API-DMAC10.html)
WO (1) WO2004024719A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05012082A (es) * 2003-05-09 2006-02-22 Pharmacia & Upjohn Co Llc Compuestos como antagonistas del receptor crf1.
US20060211710A1 (en) * 2005-03-17 2006-09-21 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
IL311645B2 (en) * 2016-07-12 2025-11-01 Revolution Medicines Inc 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors
CN110446709B (zh) 2017-01-23 2023-09-12 锐新医药公司 作为变构shp2抑制剂的二环化合物
CA3051054A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
TWI852912B (zh) 2017-09-07 2024-08-21 美商銳新醫藥公司 Shp2抑制劑組合物以及治療癌症的方法
BR112020007058A2 (pt) 2017-10-12 2020-10-06 Revolution Medicines, Inc. compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos
BR112020009757A2 (pt) 2017-12-15 2020-11-03 Revolution Medicines, Inc. compostos policíclicos como inibidores alostéricos de shp2
PL3788049T3 (pl) 2018-05-01 2023-06-19 Revolution Medicines, Inc. Połączone z C40, C28 i C32 analogi rapamycyny jako inhibitory mTOR
EP3788050B1 (en) 2018-05-01 2024-08-28 Revolution Medicines, Inc. C26-linked rapamycin analogs as mtor inhibitors
EP4531859A4 (en) 2022-05-25 2026-05-27 Revolution Medicines Inc CANCER TREATMENT METHODS USING AN MTOR INHIBITOR

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4270297A (en) * 1996-09-16 1998-04-02 Du Pont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
PA8467401A1 (es) * 1998-02-17 2000-09-29 Pfizer Prod Inc Procedimiento para tratar la insuficiencia cardiaca
IL139197A0 (en) * 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
ATE307121T1 (de) * 2000-02-16 2005-11-15 Neurogen Corp Substituierte arylpyrazine

Similar Documents

Publication Publication Date Title
RU2440330C2 (ru) ПРОИЗВОДНЫЕ 4-(2-АМИНО-1-ГИДРОКСИЭТИЛ)ФЕНОЛА, КАК АГОНИСТЫ β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА
JP2024099041A5 (cg-RX-API-DMAC10.html)
TWI457337B (zh) 呋呫基苯并咪唑
JP2021523221A5 (cg-RX-API-DMAC10.html)
AU2020223228A1 (en) Compounds, compositions and methods
WO2020167994A1 (en) Compounds, compositions and methods
JP2005514420A5 (cg-RX-API-DMAC10.html)
CA2617991A1 (en) N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
US12606525B2 (en) Dimethyltryptamine analogues as nitric oxide delivery drugs
CN116209433B (zh) 小分子白蛋白结合剂
AU2019269409A1 (en) Matrix metalloproteinase (MMP) inhibitors and methods of use thereof
JP2023109924A (ja) ジヒドロイミダゾピラジノン化合物、該化合物を含む組成物およびその使用
JP2022527075A5 (cg-RX-API-DMAC10.html)
EP1802606B1 (en) Arylcarboxamides and their use as anti-tumor agents
JP2022535794A (ja) Rip-1キナーゼ阻害剤としての二環式化合物およびその使用
JP2023547346A5 (cg-RX-API-DMAC10.html)
JP2021527102A5 (cg-RX-API-DMAC10.html)
ZA200204256B (en) Novel compounds.
JP2019023181A5 (cg-RX-API-DMAC10.html)
JP2008133274A5 (cg-RX-API-DMAC10.html)
WO2023085396A1 (ja) アルポート症候群を治療または予防するための医薬組成物
JP2013540780A (ja) イミダゾール誘導体並びにその製造法及び使用
JP2023524996A5 (cg-RX-API-DMAC10.html)
JP2023527396A5 (cg-RX-API-DMAC10.html)
KR102757745B1 (ko) 유기 키랄 촉매 화합물을 이용한 고리형 무수물의 비대칭 고리열림반응 생성물의 제조방법